Document:

EX-10.13

 Exhibit 10.13 
 EMPLOYMENT AGREEMENT 
 THIS EMPLOYMENT AGREEMENT (the
“Agreement”) is entered into the 28th day of August, 2012 by and between Spectrum Pharmaceuticals, Inc. (hereinafter referred to as the “Company”), and Joseph Kenneth Keller (“Executive”). In consideration of the mutual
covenants and agreements hereinafter set forth, the parties agree as follows: 
 1. EMPLOYMENT. 

1.1 Position. Subject to the terms and conditions set forth in this Agreement, the Company agrees to employ Executive as
the Company’s Executive Vice President and Chief Operating Officer, reporting directly to the Rajesh C. Shrotriya, M.D., the Company’s Chief Executive Officer. Executive shall begin his employment in this position on September 13,
2012. That date is hereinafter referred to as the “Effective Date.” 
 1.2 Duties. Executive shall
diligently, and to the best of his ability, perform all duties incident to his position and use his best efforts to promote the interests of the Company. 
 1.3 At-Will Employment. Executive and the Company understand and acknowledge that Executive’s employment with the Company is “at-will,” is for no specified term, and may be
terminated by Executive or the Company at any time, with or without cause or notice. Upon termination of Executive’s employment with the Company, neither Executive nor the Company shall have any further obligation or liability under this
Agreement to the other, except as specifically set forth herein. 
 1.4 Time to be Devoted to Employment.
Throughout the term of his employment, Executive shall devote his full time and energy to the business of the Company and shall not be engaged in any competitive business activity. Executive hereby represents that he is not a party to any agreement
which would be an impediment to entering into this Agreement and that he is permitted to enter into this Agreement and perform the obligations hereunder. 
 2. COMPENSATION AND BENEFITS. 
 2.1
Annual Salary. In consideration of and as compensation for the services agreed to be performed by Executive hereunder, the Company agrees to pay Executive an annual base salary of five hundred twenty-five thousand dollars ($525,000.00)
(“Base Salary”), less applicable withholdings and deductions, payable in accordance with the Company’s scheduled semi-monthly payroll distribution dates, currently the 15th and last day of the month, or the previous business day in the event the payroll date falls on a weekend or holiday.
The Base Salary will be subject to further changes at the sole discretion of the Company. 
 2.2 Bonus. Executive
shall be eligible for an annual bonus of up to 50% of his Base Salary, pro-rated for calendar year 2012, based upon the achievement of milestones to be established by the Company, payable at such time that bonuses are normally paid to executives.
Executive must be actively employed at the time the bonuses are paid to be entitled to a bonus. 

 3. RELOCATION. 

The Executive shall relocate to either Orange County, California or the Henderson area in Nevada no later than six months after the
Effective Date. At the time of such relocation, the shall Company will pay Executive a one-time bonus of $30,000; provided, however, Executive shall be obligated to pay back that amount to the Company if he should voluntarily leave his employment
with the Company or be terminated for cause within one year of the date this relocation bonus is paid. 
 For the period
beginning on the Effective Date and ending on the earliest to occur of (i) the date the aforementioned relocation is completed, (ii) the six month anniversary of the Effective Date or (iii) the termination of employment, the Company
shall reimburse Executive for up to $3,500 per month for reasonable and necessary travel and temporary living expenses, including airfare, rented/leased vehicle and accommodations, subject to receipt of reasonable and appropriate documentation as
may be required by the Company. 
 4. EQUITY AWARDS. 

Subject to approval of the Board of Directors, Executive will be eligible to receive equity awards as follows: (i) on or promptly
following the Effective Date, twenty thousand (20,000) restricted stock awards, to vest 50% upon the completion of six months employment and the other 50% upon the completion of one year of employment, as a special hire-in bonus; (ii) on
or promptly following the Effective Date, an additional one hundred thousand (100,000) restricted stock awards to vest 25% on the completion of one year of employment and the remaining 75% to vest annually in equal amounts on the completion of
Executive’s second, third and fourth years of employment; and (iii) on or promptly following the Effective Date, three hundred thousand (300,000) stock options with an exercise price equal to the closing sale price of the
Company’s stock on the date prior to the date of grant to vest 25% on the completion of one year of employment, and the remaining 75% annually in equal amounts on the completion of Executive’s second, third and fourth years of employment.
All of the foregoing grants of restricted stock awards and options are subject to the terms and conditions of the Spectrum Pharmaceuticals Inc. 2009 Incentive Award Plan (the “Plan”), and the award agreements provided for under the Plan,
as each may be amended from time to time. As provided in the Plan, vesting of all of the foregoing grants of restricted stock awards and options shall be accelerated on a Change in Control as that term is defined in the Plan. 

5. BENEFITS. 
 Executive and his dependents shall be eligible to participate in such health, retirement and other benefit programs as the Company provides to its other executive employees, including, at this time,
Medical, Vision, Long Term Disability, and Travel Accident Insurance, 401(k) Savings Plan and Employee Stock Purchase Plan. 

6. VACATION AND HOLIDAY. Executive shall be entitled to three weeks of paid vacation per year (15 business days), subject
to the terms of the Company’s vacation policy, which may be used by Executive at times which do not unreasonably interfere with the duties and responsibilities of Executive’s position, as well as paid holidays as specified by the Company.

  
 2 

 7. BUSINESS EXPENSES. The Company shall reimburse Executive for reasonable
and necessary travel and accommodation costs, entertainment and other business expenses incurred as a necessary or advisable part of discharging Executive’s duties hereunder subject to receipt of reasonable and appropriate documentation as may
be required by the Company. 
 8. INDEMNIFICATION. The Company and Executive shall enter such indemnity agreement
as is provided to similar level executives and as may be amended from time to time. 
 9. ARBITRATION. Executive
and the Company agree that to the fullest extent permitted by law, any dispute, claim or controversy of any kind arising under, in connection with or relating to this Agreement or otherwise relating to Executive’s employment by the Company,
shall be resolved exclusively by binding arbitration in Southern California and in furtherance of this provision, Executive and the Company agree to sign the Company’s standard form Arbitration Agreement. 

10. PROPRIETARY INFORMATION AND RELATED MATTERS. Executive acknowledges and agrees that Executive will be entrusted with,
among other things, trade secrets and proprietary information regarding the products, processes, methods of manufacture and delivery, know how, designs, formula, work in progress, research and development, computer software and data bases,
copyrights, trademarks, patents, marketing techniques, and future business plans, as well as customer lists and information concerning the identity, needs, and desires of actual and potential customers of the Company and its subsidiaries, joint
ventures, partners, and other affiliated persons and entities (“Confidential Information”), all of which derive significant economic value from not being generally known to others outside the Company. 

(a) During the entire term of Executive’s employment with the Company, and at all times thereafter, Executive shall not disclose or
exploit any Confidential Information except as necessary in the performance of Executive’s duties under this Agreement or with the Company’s express written consent. 
 (b) During the entire term of Executive’s employment by the Company and for two years thereafter, Executive shall not induce or attempt to induce any Executive of the Company to leave the
Company’s employ except for the sole benefit of the Company or with its express written consent. 
 In furtherance of this
agreement, Executive agrees to sign the Company’s standard form Confidentiality Agreement. 
 11. ASSIGNMENT.
This Agreement shall inure to the benefit of and shall be binding upon the successors and assigns of the Company. Since this Agreement is based upon the abilities of and personal confidence in Executive, Executive shall have no right to assign this
Agreement or any of Executive’s rights hereunder without the prior written consent of the Company. 

  
 3 

 12. SEVERABILITY. If any provision of this Agreement shall be found invalid
by any court of competent jurisdiction, such findings shall not affect the validity of any other provision hereof and the invalid provisions shall be deemed to have been severed herefrom. 

13. WAIVER OF BREACH. The waiver by any party of the breach of any provision of this Agreement by the other party or the
failure of any party to exercise any right granted to it hereunder shall not operate or be construed as the waiver of any subsequent breach by such other party nor the waiver of the right to exercise any such right. 

14. NOTICES. Any notice, consent or other communication under this Agreement shall be in writing and shall be delivered
personally, telexed, sent by facsimile transmission or overnight courier (regularly providing proof of delivery) or sent by registered, certified, or express mail and shall be deemed given when so delivered personally, telexed, sent by facsimile
transmission or overnight courier, or if mailed two (2) days after the date of deposit in the United States mail. Notice to parties shall be delivered or mailed to the following addresses (or to such other address as a party may specify by
written notice). 
  

			
	If to Executive:	  	Joseph Kenneth Keller
		  	XXXXXXXXXXXXX
		  	XXXXXXXXXXXXX
		
	If to the Company:	  	Spectrum Pharmaceuticals, Inc.
		  	11500 South Eastern Avenue, Suite 240
		  	Henderson, Nevada 89052
		  	Attn: Legal Department
		  	Fax: (702) 260-7405

 15. ENTIRE AGREEMENT. This Agreement contains the entire agreement of the parties relating
to the subject matter hereof and supersedes all agreements and understandings with respect to such subject matter not described herein, and the parties hereto have made no other agreements, representations or warranties, oral or written, relating to
the subject matter of this Agreement. 
 16. MODIFICATION. This Agreement may be amended, modified, superseded or
cancelled only by a written instrument signed by the parties. 
 17. CHOICE OF LAW. This Agreement is made under
and shall be governed by and construed in accordance with the laws of the State of Nevada without regard for conflicts of laws principles. 
 18. INTERPRETATION OF AGREEMENT. This Agreement has been negotiated at arm’s length and between persons sophisticated and knowledgeable in the matters dealt with in this Agreement.
Accordingly, any rule of law or legal decision that would require interpretation of any ambiguities in this Agreement against the party that has drafted it is not applicable and is waived. The provisions of this Agreement shall be interpreted in a
reasonable manner to effect the purpose of the parties and this Agreement. 

  
 4 

 19. HEADINGS. The headings in this Agreement are solely for the convenience
of reference and shall not affect its interpretation. 
 20. COUNTERPARTS; FACSIMILE; .PDF. This Agreement may be
executed by facsimile or .PDF and in one or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. 

IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first above written. 

 

			
	SPECTRUM PHARMACEUTICALS, INC.
		
	By:	 	 /s/ Rajesh C. Shrotriya

	Name:	 	Rajesh C. Shrotriya
	Title:	 	Chairman, CEO and President
	
	JOSEPH KENNETH KELLER
	
	     /s/ Joseph K. Keller

	Joseph Kenneth Keller

  
 5 

 FIRST AMENDMENT TO EMPLOYMENT AGREEMENT 

THIS FIRST AMENDMENT TO EMPLOYMENT AGREEMENT (the “Amendment”) is made as of the 5th day of September, 2012 (The
“Effective Date”) by and between Spectrum Pharmaceuticals, Inc. (the “Company”) and Joseph Kenneth Keller (“Executive”). 
 RECITALS. 
  

	 	A.	The Company and Executive entered into the certain Employment Agreement dated as of August 28, 2012 (the “Agreement”); and 

 

	 	B.	The Company and Executive desire to amend certain provisions of the Agreement. 

 NOW, THEREFORE, the Company and Executive agree as follows: 
 1.
AMENDMENT OF SECTION 1.1. Section 1.1 of the Agreement is hereby amended and restated to read in full as follows: 
 1.1 Position. Subject to the terms and conditions set forth in this Agreement, the Company agrees to employ Executive as the Company’s Executive Vice President and Chief Operating
Officer, reporting directly to the Rajesh C. Shrotriya, M.D., the Company’s Chief Executive Officer. Executive shall begin his employment in this position on September 1, 2012. That date is hereinafter referred to as the “Effective
Date.” 
 2. AMENDMENT OF SECTION 4. 

Section 4 of the Agreement is hereby amended and restated in its entirety to read fully as follows: 

4. EQUITY AWARDS. 
 Subject to approval of the Board of Directors, Executive will be eligible to receive equity awards as follows: (i) on or promptly following the Effective Date, twenty thousand
(20,000) restricted stock awards, to vest 50% upon the completion of six months employment and the other 50% upon the completion of one year of employment, as a special hire-in bonus; (ii) on or promptly following the Effective Date, an
additional one hundred thousand (100,000) restricted stock awards to vest 25% on the completion of one year of employment and the remaining 75% to vest annually in equal amounts on the completion of Executive’s second, third and fourth
years of employment; and (iii) on or promptly following the Effective Date, three hundred thousand (300,000) stock options with an exercise price equal to the closing sale price of the Company’s stock on the date of grant to vest 25%
on the completion of one year of employment, and the remaining 75% monthly in equal amounts during Executive’s second, third and fourth years of employment. All of the foregoing grants of restricted stock awards and options are subject to the
terms and conditions of the Spectrum Pharmaceuticals Inc. 2009 Incentive Award Plan (the “Plan”), and the award agreements provided for under the Plan, as each may be amended from time to time. As provided in the Plan, vesting of all of
the foregoing grants of restricted stock awards and options shall be accelerated on a Change in Control as that term is defined in the Plan. 

  
 6 

 3. NO OTHER AMENDMENTS. Except as amended herein, all provisions of the
Original Agreement and the Amendment shall remain in full force and effect. 
 4. COUNTERPARTS. This Amendment may
be executed in any number of counterparts and transmitted by facsimile or PDF copy, each of which shall be an original, but all of which together shall constitute one instrument. 

IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first above written. 

 

			
	SPECTRUM PHARMACEUTICALS, INC.
		
	By:	 	 /s/ Rajesh C. Shrotriya

	Name:	 	Rajesh C. Shrotriya, M.D.
	Title:	 	President and Chief Executive Officer
	
	JOSEPH KENNETH KELLER
	
	     /s/ Joseph Kenneth Keller

	Joseph Kenneth Keller

  
 7EX-10.14

 Exhibit 10.14 
 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT MARKED WITH [***] HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT, AS AMENDED. 
 OMNIBUS AMENDMENT TO ZEVALIN SUPPLY ARRANGEMENTS 

This Omnibus Amendment to Zevalin Supply Arrangements (this “Amendment”) is made effective as of the 1st day of October, 2012 by
and between Biogen Idec US Corporation, a Massachusetts corporation (“Biogen Idec”), on one hand, and RIT Oncology, LLC, a Delaware limited liability company and wholly-owned subsidiary of Spectrum Pharmaceuticals, Inc.
(“RIT”), and Spectrum Pharmaceuticals Cayman, L.P., a Cayman exempted limited partnership and wholly-owned subsidiary of Spectrum Pharmaceuticals, Inc. (“Cayman”) (RIT and Cayman, collectively,
“Spectrum”), on the other hand. Biogen Idec and Spectrum are sometimes referred to herein individually as a “Party” and collectively as the “Parties”. 

RECITALS 
 A. Biogen Idec
currently supplies Zevalin to RIT for sale within the United States. Such supply arrangement is governed by that certain Supply Agreement, dated December 21, 2007, by and between Cell Therapeutics, Inc. (“CTI”) and
Biogen Idec Inc. (“BIIB”), as amended by that certain First Amendment to Supply Agreement, dated December 15, 2008, by and between CTI and BIIB, as well as assigned by CTI to RIT on December 15, 2008 with
BIIB’s consent pursuant to that certain consent to assignment letter agreement, dated December 15, 2008, by and among CTI, BIIB and RIT and assigned by BIIB to Biogen Idec on July 1, 2011 as BIIB informed RIT by that certain letter,
dated January 27, 2012, from BIIB to RIT. Such agreement is referred to herein as the “US Supply Agreement”. 
 B.
Biogen Idec currently supplies Zevalin to Cayman for sale outside the United States. Such supply arrangement is governed by that certain Supply Agreement, dated June 9, 1999, by and between IDEC Pharmaceuticals Corporation (now known as BIIB)
and Schering Aktiengesellschaft (now known as Bayer Pharma AG), as amended by (i) that certain letter amendment, dated December 14, 2004, by and between BIIB and Schering Aktiengesellschaft (now known as Bayer Pharma AG) and (ii) that
certain Amendment to Supply Agreement, dated January 16, 2012, by and between Biogen Idec and Bayer Pharma AG (under which Bayer Pharma AG consented to BIIB assigning such agreement to Biogen Idec), as well as assigned by Bayer Pharma AG to
Cayman on April 1, 2012 as Bayer Pharma AG informed BIIB by that certain letter, dated April 3, 2012, from Bayer Pharma AG to BIIB. Such agreement is referred to herein as the “ex-US Supply Agreement”. 

C. The Parties wish to amend the US Supply Agreement and the ex-US Supply Agreement and otherwise generally provide for a cohesive worldwide supply
arrangement between Biogen Idec and Spectrum on a forward-looking basis. 
 NOW, THEREFORE, THE PARTIES AGREE AS FOLLOWS: 

1. Capitalized terms used in this Amendment without definition shall have the same meanings ascribed to them in the US Supply Agreement or the ex-US
Supply Agreement, as applicable. 

 2. Unless terminated earlier in accordance with their respective terms, the US Supply Agreement and the
ex-US Supply Agreement shall expire on December 31, 2014. Following such expiration, Biogen Idec shall have no further supply-related obligations pursuant to the US Supply Agreement or the ex-US Supply Agreement (including, without limitation,
the Collaboration Agreement or the License Agreement) other than as set forth in Sections 7 and 8 below (i.e., manufacturing transfer). Termination, relinquishment or expiration of the US Supply Agreement or the ex-US Supply Agreement
for any reason shall be without prejudice to any rights that have accrued to the benefit of either Party prior to such termination, relinquishment or expiration (including, without limitation, damages arising from any breach thereunder) and shall
automatically and concurrently terminate the other agreement. 
 3. As of the date hereof, Biogen Idec hereby sells to Spectrum, and Spectrum
hereby purchases from Biogen Idec, certain inventory related to Zevalin, which inventory includes: (i) [***] lots of Antibody Conjugate bulk solution (approximately [***] kg) expiring between [***] and [***] (ii) [***] ([***]) vials
of Antibody Conjugate (unlabeled) expiring not earlier than [***] (iii) [***] ([***]) vials of sodium acetate (unlabeled) expiring not earlier than [***]; (iv) [***] ([***]) vials of formulation buffer (unlabeled) expiring not earlier than
[***]; and (v) [***] ([***]) vials of the reaction vial (unlabeled) expiring not earlier than [***]. The price of such inventory shall be US $[***] and Sections 9.1 (Shipment and Taxes), 9.2 (Governing Terms) and 9.3 (No
Implied Representations, Warranties or Conditions) of this Amendment shall apply with respect thereto; provided, however, that payment for such price shall be due and payable in four (4) installments of US $[***] on the first
business day of each of [***], [***], [***] and [***]. On a date during [***] as agreed upon by the Parties, such inventory shall be made available for delivery to Spectrum; provided, however, that, on a date during [***] as
agreed upon by the Parties, all or any portion of such inventory shall also be made available for delivery to Spectrum. 
 4. As of the date
hereof, Biogen Idec hereby sells to Spectrum, and Spectrum hereby purchases from Biogen Idec, the equipment related to Zevalin listed on Exhibit A on an “as is” basis without any representation or warranty of any kind, express or
implied (including, without limitation, any warranties of quality, performance, merchantability or fitness for a particular use or purpose). The price of such equipment shall be US $[***] and Sections 9.1 (Shipment and Taxes) and 9.2
(Governing Terms) of this Amendment shall apply with respect thereto. On a date corresponding to the start of the single drug substance manufacturing campaign in [***] pursuant to Section 6 below as agreed upon by the Parties, such
equipment shall be made available for delivery to Spectrum. 
 5. The Parties acknowledge that, as of the date hereof, there are no outstanding
orders for Finished US Goods or Bulk Product under the US Supply Agreement or Kits under the ex-US Supply Agreement. The Parties agree that, on or after the date hereof, there shall be no orders therefor other than as set forth in
Section 6 below (i.e., a single drug substance manufacturing campaign in [***]). The Parties further agree that, on or after the date hereof, there shall be no forecasting for orders thereof. 

 

	[***]:	CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION. 

  
 - 2 -

 6. Prior to expiration or earlier termination of the US Supply Agreement and the ex-US Supply
Agreement and upon Spectrum’s written request no later than [***], Biogen Idec agrees to conduct a single drug substance manufacturing campaign, at any time within nine (9) to eighteen (18) months of such written request (i.e., the
timing during this period is in Biogen Idec’s sole discretion), to supply Spectrum with [***] batches of 2B8 (i.e., the drug substance antibody) produced using [***] liter bioreactors. Spectrum shall purchase from Biogen Idec all 2B8
produced from such batches, provided that the quantity produced is no less than [***] grams but no more than [***] grams. Spectrum shall make such written request pursuant to a single purchase order sent in a manner and format consistent with Biogen
Idec’s reasonable direction. The price of such 2B8 shall be US $[***] per gram of active weight antibody for the first [***] grams and US $[***] per gram of active weight antibody for any additional grams and Sections 9.1 (Shipment and
Taxes), 9.2 (Governing Terms) and 9.3 (No Implied Representations, Warranties or Conditions) of this Amendment shall apply with respect to any such 2B8 ordered pursuant to this Section 6 mutatis mutandis; provided,
however, that, no later than [***] ([***]) days before the start of such single drug substance manufacturing campaign, Spectrum shall deposit funds for advance payment of [***] percent ([***]%) of such price into an escrow account with an
escrow agent reasonably acceptable to Biogen Idec (it being understood that any escrow agreement, joint instructions or other terms of escrow release shall provide for the immediate release of funds to Biogen Idec upon delivery of the 2B8 ordered
pursuant to this Section 6). The remaining [***] percent ([***]%) of the price shall be due and payable upon such delivery. For the avoidance of doubt, Biogen Idec’s obligation to conduct such single drug substance manufacturing
campaign is conditioned upon the Parties identifying such escrow agent, the Parties executing and delivering the applicable escrow agreement, joint instructions or other terms of escrow release, which Biogen Idec will not unreasonably prevent or
delay, and Spectrum depositing such funds into such escrow account (i.e., Biogen Idec shall have no liability or other obligation pursuant to this Section 6 until such condition is fully satisfied). 

7. The Parties agree that, on and after the date hereof, Spectrum shall be responsible for analytical services, fill/finish activities, conjugation
activities and all other drug product activities for Zevalin. Without prejudice to the generality of the foregoing, the Parties agree to the following: 
 (a) Spectrum shall submit any and all applicable regulatory submissions to the appropriate regulatory authority in all jurisdictions as soon as reasonably possible for the transitioning of Zevalin
contemplated by this Section 7 and otherwise no later than [***] ([***]) months after completion of the applicable validation. 
 (b) In the event that Spectrum undertakes commercially reasonable efforts to conduct conjugation activities at [***] (as defined below) and such efforts fail to deliver the Antibody Conjugate, then, upon
Spectrum’s written request no later than June 30, 2014, Biogen Idec agrees to conduct conjugation activities, at any time during 2014 in Biogen Idec’s sole discretion, for 2B8 (i.e., the drug substance antibody) that Spectrum ordered
and received pursuant to Section 6 above. Such conjugation activities shall be performed by Biogen Idec [***] but shall be limited to Biogen Idec’s labor performed at Biogen Idec’s Cambridge, MA facility as consistent with
Biogen Idec’s past labor practices necessary to perform conjugation activities for 2B8. Spectrum shall be responsible in all other manners for such conjugation activities (including, without limitation, supplying all of the drug substance
antibody, equipment, raw materials and consumable materials appropriate for such conjugation activities and arranging for shipment to and from such facility of such drug substance antibody, equipment, raw materials and consumable materials and the
Antibody Conjugate resulting from such conjugation activities, as well as paying for all costs and expenses with respect thereto). Notwithstanding any provision herein to the contrary, the Parties acknowledge and agree that Biogen Idec shall have no
further responsibility with respect to such conjugation activities upon completion of a single conjugation campaign. 
  

	[***]:	CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION. 

  
 - 3 -

 (c) As of the date hereof, Spectrum hereby assumes liability and project management from
BIIB of all responsibilities and obligations accruing on or after the date hereof under that certain Amended and Restated Commercial Supply Agreement, dated January 25, 2008, by and between BIIB and Baxter Pharmaceutical Solutions LLC
(“Baxter”), as amended by (i) that certain letter, dated October 12, 2009, from Baxter to BIIB and (ii) that certain letter, dated December 9, 2010, from Baxter to BIIB (signed by BIIB on December 28,
2010). Biogen Idec shall use commercially reasonable efforts from the date hereof through October 31, 2012 to obtain Baxter’s written consent to the assignment of such agreement by BIIB to RIT (it being understood that Biogen Idec shall
not be required to make any payment or provide any guarantee in order to obtain such consent) and, thereupon, Biogen Idec shall cause BIIB to assign such agreement to RIT. Spectrum shall assist BIIB in such efforts. To the extent such consent has
not been obtained by October 31, 2012, Spectrum shall use commercially reasonable efforts to have Baxter and RIT enter into a replacement agreement for such agreement (which, among other things, terminates such agreement and any further
liability of BIIB thereunder). In the event that neither an assignment of nor replacement for such agreement is achieved within a reasonable period of time, Biogen Idec shall use commercially reasonable efforts to provide the benefits of such
contract to Spectrum (by reserving “fill slots” with Baxter) during 2012 so long as Spectrum bears all costs, expenses and other liabilities in connection therewith. Upon Spectrum’s written request, Biogen Idec shall sell to Spectrum,
and Spectrum shall purchase from Biogen Idec, the equipment related to Zevalin owned by Biogen Idec but held by Baxter at Baxter’s facility in connection with such agreement on an “as is” basis without any representation or warranty
of any kind, express or implied (including, without limitation, any warranties of quality, performance, merchantability or fitness for a particular use or purpose). The price of such equipment shall be US $[***] and Spectrum shall be responsible in
all manners for removing such equipment from Baxter’s facility (including, without limitation, coordinating with Baxter and arranging for shipment of such equipment, as well as paying for all costs and expenses with respect thereto).

 (d) Spectrum shall use commercially reasonable efforts to engage [***], Inc. (“[***]”) as its contract
manufacturing organization for fill/finish activities for Zevalin. Within [***] ([***]) days of receipt of Spectrum’s invoice and reasonable supporting documentation therefor, Biogen Idec agrees to reimburse Spectrum for [***] of the amount
actually paid by Spectrum to [***] and any applicable third party testing laboratories for [***] fill/finish technology transfer for Zevalin; provided, however, that such reimbursement shall be no greater than US $[***] in the
aggregate. For the avoidance of doubt, such reimbursement applies solely for activities in support of fill/finish technology transfer and not to any other matters handled by [***] (including, without limitation, validation activities). For the
avoidance of doubt, such reimbursement shall include payments made by Spectrum to third party testing laboratories that play a role in the technology transfer qualification of [***]. 

 

	[***]:	CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION. 

  
 - 4 -

 (e) Biogen Idec shall use commercially reasonable efforts to provide Spectrum with technical
advice reasonably necessary to effect the subcontracting and/or transitioning of Zevalin contemplated by this Section 7 to the extent specifically listed as a Biogen Idec responsibility on the project plan attached as Exhibit B.
Notwithstanding any provision herein to the contrary, the Parties acknowledge and agree that Biogen Idec shall have no further responsibility with respect to such technical advice upon completion of a single subcontracting and/or transitioning of
Zevalin. 
 The Parties recognize and accept that the obligations of this Section 7 shall survive expiration or earlier termination
of the US Supply Agreement and the ex-US Supply Agreement. 
 8. Upon Spectrum’s written request at least twelve (12) months prior to
the anticipated start date for the activities required to effect an orderly transition of the manufacture of 2B8 (i.e., the drug substance antibody) from Biogen Idec to Spectrum or its designee, Biogen Idec and Spectrum shall exercise fair dealing
and negotiate in good faith to agree upon a project plan describing such activities (the “Project Plan”), and the Parties shall subsequently implement the Project Plan. Without prejudice to the generality of the foregoing,
the Project Plan shall include or address the following: 
 (a) the cost and expense of Biogen Idec’s personnel and
resources used in connection with the implementation of the Project Plan will be borne by Biogen Idec; 
 (b) Biogen Idec
delivering or providing access to Spectrum or its designee of documentation reasonably necessary to effect such transition in an orderly manner consistent with regulatory requirements, including documentation summarizing any BIOGEN IDEC Know-How;

 (c) if Spectrum requests, Cayman or its designee obtaining the same rights as BIIB’s rights under that certain Amended
and Restated Non-Exclusive License Agreement, dated as of December 20, 2007, by and between Genentech, Inc. and BIIB (which is commonly referred to by Biogen Idec as its “Cabilly license”) in connection with the manufacture of Zevalin
outside the United States through a direct license from Genentech, Inc. to Cayman or its designee or, if a direct license cannot be achieved after the use of commercially reasonable efforts, a sublicense from BIIB to Cayman or its designee (it being
understood that Cayman or its designee shall enter into a sublicense agreement for such sublicense in substantially the same form and substance as the similar sublicense by BIIB to RIT for the manufacture of Zevalin within the United States in
existence as of the date hereof); and 
 (d) limitations on the type, number, frequency and length of meetings, document
requests and the like, as well as procedures and timelines with the aim of efficiently using Biogen Idec’s personnel and resources and otherwise minimizing cost and expense in connection therewith. 

  
 - 5 -

 In furtherance of the foregoing, Biogen Idec’s obligations under the Project Plan shall be limited to
(i) providing appropriate answers to specific, reasonable questions only during normal business hours and (ii) no more than a total of [***] ([***]) person-days of time, in the aggregate for all participation, by all Biogen Idec personnel.
Spectrum acknowledges and agrees that Biogen Idec’s obligations under this Section 8 are limited in accordance with the Project Plan and are dependent upon (x) the reasonable competence of Spectrum or its designee with respect
to the activities at issue (including, without limitation, obtaining the required approvals in a timely manner for the conduct of manufacturing activities at a facility selected and prepared by Spectrum or its designee and possession by Spectrum or
its designee of the requisite skills, equipment, ingredients and resources for the manufacture of product similar to Zevalin) and (y) Spectrum’s timely performance of its obligations under Section 7 above, this
Section 8 and the Project Plan. Notwithstanding any provision herein to the contrary, the Parties acknowledge and agree that Biogen Idec shall be obligated to participate in the manufacturing transfer activities contemplated by this
Section 8 only once and that, subject as stated below, Biogen Idec shall have no further responsibility with respect to such activities thereafter. In the event that such transition is not successfully achieved through no fault of Biogen
Idec or Spectrum, Biogen Idec agrees to provide reasonable additional assistance if requested by Spectrum, provided that Spectrum shall pay for any costs and expenses associated with such additional assistance. Such costs and expenses shall be
reasonable and shall be directly referable to the activities to be performed. The Parties recognize and accept that the obligations of this Section 8 shall survive expiration or earlier termination of the US Supply Agreement and the
ex-US Supply Agreement. 
 9. The following provisions shall apply with respect to delivery of materials under this Amendment: 

9.1 Shipment and Taxes: All materials shipped under this Amendment with reference to this Section 9.1 shall be shipped EXW
the manufacturing site to such location designated by Spectrum. Spectrum shall pay all freight, insurance, charges, Taxes, levies, import and export duties, inspection fees and other charges applicable to the sale and transport of such materials.
Title and risk of loss and damages to such materials shall pass to Spectrum (and delivery to Spectrum shall be deemed to occur) upon delivery to the carrier at the manufacturing site. In the event of damage or loss to such materials after delivery
to carrier, Spectrum shall be responsible to file claims with the carrier. Biogen Idec shall cooperate with Spectrum in the filing of such claims. 
 9.2 Governing Terms: All sales of materials under this Amendment with reference to this Section 9.2 shall not be subject to any terms and conditions contained on any purchase orders submitted
by Spectrum, except insofar as any such purchase orders establish in writing: (i) the delivery date, consistent with the terms hereof; (ii) the shipment routes; or (iii) the carrier selected by Spectrum. 

 

	[***]:	CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION. 

  
 - 6 -

 9.3 No Implied Representation, Warranties or Conditions: Biogen Idec warrants that each of
the materials supplied under this Amendment with reference to this Section 9.3 shall meet the applicable Specifications and shall be manufactured according to CGMPs and in accordance with provisions of any applicable quality agreement;
provided, however, that Spectrum’s sole remedy with respect to non-compliance with the foregoing warranty for any materials supplied pursuant to Section 3 (i.e., inventory as of the date hereof) shall only apply after
such non-compliance applies to more than [***] percent ([***]%) of such inventory in the aggregate, upon which Spectrum may claim a reduction of the price applicable to such inventory in excess of such [***] percent ([***]%) (it being understood
that such [***] percent ([***]%) threshold acts as a deductible for which Spectrum is solely responsible) in an amount of Spectrum’s direct damages incurred as a result of such non-compliance. For the purposes of further defining the provision
in the previous sentence, the [***] percent ([***]%) is relative to the US $[***] price that is described in Section 3, and the inventory is assigned the following prices: (i) seven (7) lots of Antibody Conjugate bulk solution
(approximately 64 kg) expiring between April and July 2013 have a total price of $[***]; (ii) [***] ([***]) vials of Antibody Conjugate (unlabeled) expiring not earlier than November 2015 have a price per vial of $[***] and a total price of
$[***]; (iii) [***] ([***]) vials of sodium acetate (unlabeled) expiring not earlier than April 2014 have a price per vial of $[***] and a total price of $[***]; (iv) [***] ([***]) vials of formulation buffer (unlabeled) expiring not
earlier than November 2013 have a price per vial of $[***] and a total price of $[***]; and (v) [***] ([***]) vials of the reaction vial (unlabeled) expiring not earlier than April 2015 have a price per vial of $[***] and a total price of
$[***]. EXCEPT AS OTHERWISE EXPRESSELY HEREIN PROVIDED, BIOGEN IDEC MAKES NO REPRESENTATIONS OR WARRANTIES AND THERE ARE NO CONDITIONS EXPRESSED OR IMPLIED, STATUTORY OR OTHERWISE, WITH RESPECT TO SUCH MATERIALS SUPPLIED HEREUNDER, INCLUDING,
WITHOUT LIMITATION, ANY SUCH REPRESENTATIONS, WARRANTIES OR CONDITIONS WITH RESPECT TO THE NON-INFRINGEMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OF SUCH MATERIALS. 
 10. Except as expressly amended by this Amendment, the US Supply Agreement and the ex-US Supply Agreement remain in full force and effect. To the extent of any conflict between the US Supply Agreement and
the ex-US Supply Agreement in the interpretation of this Amendment, the US Supply Agreement shall control. 
 11. This Amendment shall be
binding upon and inure to the benefit of the Parties and their respective successors and assigns. This Amendment may be executed in separate counterparts, each of which shall be deemed an original and all of which together shall constitute one and
the same instrument. Signatures on counterparts of this Amendment transmitted by facsimile or e-mail shall be deemed effective for all purposes. 
 [SIGNATURE PAGE FOLLOWS] 
  

	[***]:	CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION. 

  
 - 7 -

 IN WITNESS WHEREOF, the Parties have executed and delivered this Amendment by their duly authorized
officers and representatives as of the date hereof. 
  

									
	BIOGEN IDEC US CORPORATION	 		 	RIT ONCOLOGY, LLC
		 		 	By: Spectrum Pharmaceuticals, Inc.
					
	By:	 	 /s/ George A. Scangos
	 		 	By:	 	/s/ Rajesh C. Shrotriya
	Name:	 	George A. Scangos	 		 	Name:	 	Rajesh C. Shrotriya
	Title:	 	CEO	 		 	Title:	 	President and Chief Executive Officer
				
		 		 		 	SPECTRUM PHARMACEUTICALS
		 		 		 	CAYMAN, L.P.
				
		 		 		 	By: Spectrum Pharmaceuticals International
		 		 		 	Holdings, LLC
		 		 		 	Its:	 	General Partner
					
		 		 		 	By:	 	Spectrum Pharmaceuticals, Inc.
		 		 		 	Its:	 	Managing Member
					
		 		 		 	By:	 	 /s/ Rajesh C. Shrotriya

		 		 		 	Name:	 	Rajesh C. Shrotriya
		 		 		 	Title:	 	President and Chief Executive Officer

 EXHIBIT A 

PURCHASED EQUIPMENT 
 [***] 
  

	[***]:	CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION. 

 EXHIBIT B 

PROJECT PLAN FOR SECTION 7 SUBCONTRACTING AND/OR TRANSITIONING 

(attached) 

[***] 
  

	[***]:	CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00209-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00209-of-00352.parquet"}]]